Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2020 / N 2

Место w3-полиненасыщенных жирных кислот при лечении больных с атеросклерозом и нарушениями липидного обмена
А.В. Сусеков

Список литературы

1. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019 Nov;290:140-205.
2. Grundy SM, Stone NJ, Bailey C, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 2019 Jun 18;139(25):e1082-143.
3. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low density lipoprotein cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2017 Aug;38(32):2459-72.
4. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, Taskinen MR, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2020 Jun;41(24):2313-30.
5. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet 2010 Nov;376(9753):1670-81.
6. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R; Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet 2012;380:581-90.
7. Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Grazia Franzosi MG, Baigent C, Keech A; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomized trials. The Lancet 2015 Apr;385(9976):1397-405.
8. Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients 2013 Mar;5(3):981-1001.
9. Varbo A, Benn M, Smith GD, Timpson NJ, Tybjaerg-Hansen A, Nordestgaard BG. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circulation Research 2015 Feb;116(4):665-73.
10. Сусеков А.В. Фенофибрат при лечении больных с гипертриглицеридемиями и атеросклерозом, новые данные. Лечебное дело 2020;1:24-37.
11. Cholewski M, Tomczykowa M, Tomczyk M. A comprehensive review of chemistry, sources and bioavailability of omega-3 fatty acids. Nutrients 2018 Nov;10(11):1662.
12. Kromann N, Green A. Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Medica Scandinavica 1980;208(5):401-6.
13. Middaugh JP. Cardiovascular deaths among Alaskan natives, 1980-86. American Journal of Public Health 1990 Mar;80(3):282-5.
14. Newman WP, Middaugh JP, Propst MT, Rogers DR. Atherosclerosis in Alaska natives and non-natives. The Lancet 1993 Apr;341(8852):1056-7.
15. Wann SL, Naruta J, Blankstein R, Thompson RC, Frohlich B, Finch CE, Thomas GS. Atherosclerosis in 16th-century Greenlandic Inuit mummies. JAMA Network Open 2019 Dec;2(12):e1918210.
16. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? European Heart Journal 2012 Feb;33(4):436-43.
17. Grosso G, Galvano F, Mearventano S, Malaguarnera M, Bucolo C, Drago F, Caraci F. Omega-3 fatty acids and depression: scientific evidence and biological mechanisms. Oxidative Medicine and Cellular Longevity 2014;2014:313570.
18. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclea factor kappaB signaling in atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 May;25(5):904-14.
19. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Current Atherosclerosis Reports 2001 Jan;3(1):83-92.
20. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC . Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998 Nov;98(19):2088-93.
21. Gao JY, Yasuda S, Tsuburaya R, Ito Y, Shiroto T, Hao K, Aizawa K, Kikuchi Y, Ito K, Shimokawa H. Long-term treatment with eicosapentaenoic acid ameliorates myocardial ischemia-reperfusion injury in pigs in vivo. Involvement of Rho-kinase pathway inhibition. Circulation Journal 2011;75(8):1843-51.
22. Swann PG, Venton DL, Le Breton GC. Eicosapentaenoic acid and docosahexaenoic acid are antagonists at the thromboxane A2/prostaglandin H2 receptor in human platelets. FEBS Letters 1989 Jan;243(2):244-6.
23. Kaminski WE, Jendraschak E, Kiefl R, von Schacky C. Dietary omega-3 fatty acids lower levels of platelet-derived growth factor mRNA in human mononuclear cells. Blood 1993 Apr;81(7):1871-9.
24. Backes J, Anzalone D, Hilleman D, Cattini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids in Health and Disease 2016 Jul;15(1):118.
25. Shearer GC, Savinova OV, Harris WS. Fish oil – how does it reduce plasma triglycerides? Biochimica et Biophysica Acta 2012;1821:843-51.
26. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum TGs? Current Opinion in Lipidology 2006 Aug;17(4):387-93.
27. Lang CA, Davis RA. Fish oil fatty acids impair VLDL assembly and/or secretion by cultured rat hepatocytes. Journal of Lipid Research 1990 Nov;31(11):2079-86.
28. Ooi EM, Watts GF, Ng TW, Barrett PH. Effect of dietary fatty acids on human lipoprotein metabolism: a comprehensive update. Nutrients 2015 Jun;7(6):4416-25.
29. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. American Journal of Cardiology 2006 May;98(44):27i-33i.
30. Wang H, Chen X, Fisher EA. N-3 fatty acids stimulate intracellular degradation of apoprotein B in rat hepatocytes. The Journal of Clinical Investigation 1993 Apr;91(4):1380-9.
31. Shimokawa H, Vanhoutte PM. Dietary omega 3 fatty acids and endothelium-dependent relaxations in porcine coronary arteries. American Journal of Physiology. Heart and Circulatory Physiology 1989 Apr;256(4):H968-73.
32. Shimokawa H, Aarhus LL, Vanhoutte PM. Dietary omega 3 polyunsaturated fatty acids augment endothelium-dependent relaxation to bradykinin in coronary microvessels of the pig. British Journal of Pharmacology 1988 Dec;95(4):1191-6.
33. Shimokawa H, Vanhoutte PM. Dietary cod-liver oil improves endothelium-dependent responses in hypercholesterolemic and atherosclerotic porcine coronary arteries. Circulation 1988 Dec;78(6):1421-30.
34. Komori K, Shimokawa H, Vanhoutte PM. Endothelium-dependent relaxation to aggregating platelets in porcine femoral veins and its modulation by diets. Circulation 1989 Aug;80(2):401-9.
35. Tagawa T, Hirooka Y, Shimokawa H, Hironaga K, Sakai K, Oyama J, Takeshita A. Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease. Hypertension Research 2002 Nov;25(6):823-9.
36. Li Q, Zhang Q, Wang M, Liu F, Zhao S, Ma J, Luo N, Li N, Li Y, Xu G, Li J. Docosahexaenoic acid affects endothelial nitric oxide synthase in caveolae. Archives of Biochemistry and Biophysics 2007 Oct;466(2):250-9.
37. Hallaq H, Smith TW, Leaf A. Modulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acids. Proceedings of the National Academy of Sciences of the USA 1992 Mar;89(5):1760-4.
38. Tsuburaya R, Yasuda S, Ito Y, Shiroto T, Gao JY, Ito K, Shimokawa H. Eicosapentaenoic acid reduces ischemic ventricular fibrillation via altering monophasic action potential in pigs. Journal of Molecular and Cell Cardiology 2011 Sep;51(3):329-36.
39. Christensen JH, Schmidt EB. Autonomic nervous system, heart rate variability and n-3 fatty acids. Journal of Cardiovascular Medicine (Hagerstown, Md.) 2007 Sep;8(Suppl 1):S19-22.
40. Yasuda S, Shimokawa H. Potential usefulness of fish oil in the primary prevention of acute coronary syndrome. European Heart Journal 2010 Jan;31(1):15-6.
41. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. The Lancet 2003 Feb;361(9356):477-85.
42. GISSI Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. The Lancet 1999 Aug;354(9177):447-55.
43. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coron-ary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. The Lancet 2007 Mar;369(9567):1090-8.
44. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. The Lancet 2008 Oct;372(9645):1223-30.
45. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. The New England Journal of Medicine 2019 Jan;380(1):11-22.
46. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F; GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002 Apr;105(6):1897-903.
47. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 Fatty acids and cardiovascular events after myocardial infarction. The New England Journal of Medicine 2010 Nov;363(21):2015-26.
48. Roncaglione MC, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, Marzona I, Milani V, Silletta MG, Tognoni G, Marchioli R; Risk and Prevention Study Collaborative Group. n-3 Fatty acids in patients with multiple cardiovascular risk factors. The New England Journal of Medicine 2013 May;368(19):1800-8.
49. Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Sarah Parish S, Armitage A; ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. The New England Journal of Medicine 2018 Oct;379(16):1540-50.
50. Manson JE, Bassuk SS, Buring JE; VITAL Research Group. Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials. The Journal of Steroid Biochemistry and Molecular Biology 2020 Apr;198:105522.
51. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J; OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010 Nov;122(21):2152-9.
52. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010 Nov;341:c6273.
53. ORIGIN Trial Investigators; Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. The New England Journal of Medicine 2012 Jul;367(4):309-18.
54. Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. Journal of Clinical Lipidology 2014 Jan-Feb;8(1):94-106.
55. Stroes ESG, Susekov AV, de Bruin TWA, Kvarnstrom M, Yang H, Davidson MH. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. Journal of Clinical Lipidology 2018 Mar-Apr;12(2):321-30.
56. Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clinical Cardiology 2018 Oct;41(10):1281-8.
57. Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova compared to Lovaza) in a pharmacokinetic single-dose evaluation) study. Journal of Clinical Lipidology 2012 Nov-Dec;6(6):573-84.
58. Calò L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A, Pandozi C, Staibano M, Santini M. n-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. Journal of the American College of Cardiology 2005 May;45(10):1723-8.
59. Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, Kang JX, Cox B, Zhang H, Schoenfeld D; Fatty Acid Antiarrhythmia Trial Investigators. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005 Nov;112(18):2762-8.
60. O’Keefe JH Jr, Abuissa H, Sastre A, Steinhaus DM, Harris WS. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. The American Journal of Cardiology 2006 Apr;97(8):1127-30.
61. Geleijnse JM , Giltay EJ, Grobbee DE, Donders ART, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. Journal of Hypertension 2002 Aug;20(8):1493-9.
62. Harris WS, Ginsberg H, Arunakul N, Shachter NS, Windsor SL, Adams M, Berglund L, Osmundsen K. Safety and efficacy of omacor in sever hypertriglyceridemia. Journal of Cardiovascular Risk 1997 Oct-Dec;4(5-6):385-91.
63. Brinton E, Mason RP. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids in Health and Disease 2017 Jan;16(1):23.
64. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). The American Journal of Cardiology 2011 Sep;108(5):682-90.
65. Epadel [package insert, 2015 and pharmaceutical interview form, 2013]. Tokyo, Japan: Mochida Pharmaceutical Co. Ltd; 2015.
66. Vascepa [package insert, 2015]. Bedminster, NJ: Amarin Pharma Inc; 2020.
67. Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clinical Therapeutics 2013 Sep;35(9):1400-11.e1-3.
68. Национальное общество по изучению атеросклероза (НОА); Российское кардиологическое общество (РКО); Российская диабетическая ассоциация (РДА). Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации, VII пересмотр. Атеросклероз и дислипидемии 2020;1(38):47:7-40.
69. Клинические Рекомендации ОССН-РКО-РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН) диагностика, профилактика и лечение. Кардиология 2018;58(6S):10-144.
70. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice 2017 Apr;23(Suppl 2):1-87.
71. Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FK; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation 2019 Sep;140(12):e673-91.

References

1. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019 Nov;290:140-205.
2. Grundy SM, Stone NJ, Bailey C, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 2019 Jun 18;139(25):e1082-143.
3. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgözoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low density lipoprotein cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2017 Aug;38(32):2459-72.
4. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, Taskinen MR, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal 2020 Jun;41(24):2313-30.
5. Cholesterol Treatment Trialists’ (CTT) Collaboration; Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Grazia Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomized trials. The Lancet 2015 Apr;385(9976):1397-405.
6. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R; Cholesterol Treatment Trialists (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet 2012;380:581-90.
7. Fulcher J, O’Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Grazia Franzosi MG, Baigent C, Keech A; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomized trials. The Lancet 2015 Apr;385(9976):1397-405.
8. Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients 2013 Mar;5(3):981-1001.
9. Varbo A, Benn M, Smith GD, Timpson NJ, Tybjaerg-Hansen A, Nordestgaard BG. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circulation Research 2015 Feb;116(4):665-73.
10. Susekov AV. Fenofibrate for treatment in patients with hypertriglyceridemia and atherosclerosis: new data. Lechebnoye Delo 2020;1:24-37 (In Russian).
11. Cholewski M, Tomczykowa M, Tomczyk M. A comprehensive review of chemistry, sources and bioavailability of omega-3 fatty acids. Nutrients 2018 Nov;10(11):1662.
12. Kromann N, Green A. Epidemiological studies in the Upernavik district, Greenland. Incidence of some chronic diseases 1950-1974. Acta Medica Scandinavica 1980;208(5):401-6.
13. Middaugh JP. Cardiovascular deaths among Alaskan natives, 1980-86. American Journal of Public Health 1990 Mar;80(3):282-5.
14. Newman WP, Middaugh JP, Propst MT, Rogers DR. Atherosclerosis in Alaska natives and non-natives. The Lancet 1993 Apr;341(8852):1056-7.
15. Wann SL, Naruta J, Blankstein R, Thompson RC, Frohlich B, Finch CE, Thomas GS. Atherosclerosis in 16th-century Greenlandic Inuit mummies. JAMA Network Open 2019 Dec;2(12):e1918210.
16. Kromhout D, Yasuda S, Geleijnse JM, Shimokawa H. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? European Heart Journal 2012 Feb;33(4):436-43.
17. Grosso G, Galvano F, Mearventano S, Malaguarnera M, Bucolo C, Drago F, Caraci F. Omega-3 fatty acids and depression: scientific evidence and biological mechanisms. Oxidative Medicine and Cellular Longevity 2014;2014:313570.
18. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclea factor kappaB signaling in atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 2005 May;25(5):904-14.
19. Fruchart JC, Staels B, Duriez P. The role of fibric acids in atherosclerosis. Current Atherosclerosis Reports 2001 Jan;3(1):83-92.
20. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC . Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998 Nov;98(19):2088-93.
21. Gao JY, Yasuda S, Tsuburaya R, Ito Y, Shiroto T, Hao K, Aizawa K, Kikuchi Y, Ito K, Shimokawa H. Long-term treatment with eicosapentaenoic acid ameliorates myocardial ischemia-reperfusion injury in pigs in vivo. Involvement of Rho-kinase pathway inhibition. Circulation Journal 2011;75(8):1843-51.
22. Swann PG, Venton DL, Le Breton GC. Eicosapentaenoic acid and docosahexaenoic acid are antagonists at the thromboxane A2/prostaglandin H2 receptor in human platelets. FEBS Letters 1989 Jan;243(2):244-6.
23. Kaminski WE, Jendraschak E, Kiefl R, von Schacky C. Dietary omega-3 fatty acids lower levels of platelet-derived growth factor mRNA in human mononuclear cells. Blood 1993 Apr;81(7):1871-9.
24. Backes J, Anzalone D, Hilleman D, Cattini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids in Health and Disease 2016 Jul;15(1):118.
25. Shearer GC, Savinova OV, Harris WS. Fish oil – how does it reduce plasma triglycerides? Biochimica et Biophysica Acta 2012;1821:843-51.
26. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum TGs? Current Opinion in Lipidology 2006 Aug;17(4):387-93.
27. Lang CA, Davis RA. Fish oil fatty acids impair VLDL assembly and/or secretion by cultured rat hepatocytes. Journal of Lipid Research 1990 Nov;31(11):2079-86.
28. Ooi EM, Watts GF, Ng TW, Barrett PH. Effect of dietary fatty acids on human lipoprotein metabolism: a comprehensive update. Nutrients 2015 Jun;7(6):4416-25.
29. Davidson MH. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. American Journal of Cardiology 2006 May;98(44):27i-33i.
30. Wang H, Chen X, Fisher EA. N-3 fatty acids stimulate intracellular degradation of apoprotein B in rat hepatocytes. The Journal of Clinical Investigation 1993 Apr;91(4):1380-9.
31. Shimokawa H, Vanhoutte PM. Dietary omega 3 fatty acids and endothelium-dependent relaxations in porcine coronary arteries. American Journal of Physiology. Heart and Circulatory Physiology 1989 Apr;256(4):H968-73.
32. Shimokawa H, Aarhus LL, Vanhoutte PM. Dietary omega 3 polyunsaturated fatty acids augment endothelium-dependent relaxation to bradykinin in coronary microvessels of the pig. British Journal of Pharmacology 1988 Dec;95(4):1191-6.
33. Shimokawa H, Vanhoutte PM. Dietary cod-liver oil improves endothelium-dependent responses in hypercholesterolemic and atherosclerotic porcine coronary arteries. Circulation 1988 Dec;78(6):1421-30.
34. Komori K, Shimokawa H, Vanhoutte PM. Endothelium-dependent relaxation to aggregating platelets in porcine femoral veins and its modulation by diets. Circulation 1989 Aug;80(2):401-9.
35. Tagawa T, Hirooka Y, Shimokawa H, Hironaga K, Sakai K, Oyama J, Takeshita A. Long-term treatment with eicosapentaenoic acid improves exercise-induced vasodilation in patients with coronary artery disease. Hypertension Research 2002 Nov;25(6):823-9.
36. Li Q, Zhang Q, Wang M, Liu F, Zhao S, Ma J, Luo N, Li N, Li Y, Xu G, Li J. Docosahexaenoic acid affects endothelial nitric oxide synthase in caveolae. Archives of Biochemistry and Biophysics 2007 Oct;466(2):250-9.
37. Hallaq H, Smith TW, Leaf A. Modulation of dihydropyridine-sensitive calcium channels in heart cells by fish oil fatty acids. Proceedings of the National Academy of Sciences of the USA 1992 Mar;89(5):1760-4.
38. Tsuburaya R, Yasuda S, Ito Y, Shiroto T, Gao JY, Ito K, Shimokawa H. Eicosapentaenoic acid reduces ischemic ventricular fibrillation via altering monophasic action potential in pigs. Journal of Molecular and Cell Cardiology 2011 Sep;51(3):329-36.
39. Christensen JH, Schmidt EB. Autonomic nervous system, heart rate variability and n-3 fatty acids. Journal of Cardiovascular Medicine (Hagerstown, Md.) 2007 Sep;8(Suppl 1):S19-22.
40. Yasuda S, Shimokawa H. Potential usefulness of fish oil in the primary prevention of acute coronary syndrome. European Heart Journal 2010 Jan;31(1):15-6.
41. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, Gallagher PJ, Calder PC, Grimble RF. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. The Lancet 2003 Feb;361(9356):477-85.
42. GISSI Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. The Lancet 1999 Aug;354(9177):447-55.
43. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coron-ary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. The Lancet 2007 Mar;369(9567):1090-8.
44. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. The Lancet 2008 Oct;372(9645):1223-30.
45. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. The New England Journal of Medicine 2019 Jan;380(1):11-22.
46. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F; GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002 Apr;105(6):1897-903.
47. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 Fatty acids and cardiovascular events after myocardial infarction. The New England Journal of Medicine 2010 Nov;363(21):2015-26.
48. Roncaglione MC, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, Marzona I, Milani V, Silletta MG, Tognoni G, Marchioli R; Risk and Prevention Study Collaborative Group. n-3 Fatty acids in patients with multiple cardiovascular risk factors. The New England Journal of Medicine 2013 May;368(19):1800-8.
49. Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Sarah Parish S, Armitage A; ASCEND Study Collaborative Group. Effects of n-3 fatty acid supplements in diabetes mellitus. The New England Journal of Medicine 2018 Oct;379(16):1540-50.
50. Manson JE, Bassuk SS, Buring JE; VITAL Research Group. Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials. The Journal of Steroid Biochemistry and Molecular Biology 2020 Apr;198:105522.
51. Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, Gottwik M, Steinbeck G, Del Castillo U, Sack R, Worth H, Katus H, Spitzer W, Sabin G, Senges J; OMEGA Study Group. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010 Nov;122(21):2152-9.
52. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S; SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010 Nov;341:c6273.
53. ORIGIN Trial Investigators; Bosch J, Gerstein HC, Dagenais GR, Diaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. The New England Journal of Medicine 2012 Jul;367(4):309-18.
54. Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. Journal of Clinical Lipidology 2014 Jan-Feb;8(1):94-106.
55. Stroes ESG, Susekov AV, de Bruin TWA, Kvarnstrom M, Yang H, Davidson MH. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. Journal of Clinical Lipidology 2018 Mar-Apr;12(2):321-30.
56. Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundström T, Wolski K, Nissen SE. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. Clinical Cardiology 2018 Oct;41(10):1281-8.
57. Davidson MH, Johnson J, Rooney MW, Kyle ML, Kling DF. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova compared to Lovaza) in a pharmacokinetic single-dose evaluation) study. Journal of Clinical Lipidology 2012 Nov-Dec;6(6):573-84.
58. Calò L, Bianconi L, Colivicchi F, Lamberti F, Loricchio ML, de Ruvo E, Meo A, Pandozi C, Staibano M, Santini M. n-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. Journal of the American College of Cardiology 2005 May;45(10):1723-8.
59. Leaf A, Albert CM, Josephson M, Steinhaus D, Kluger J, Kang JX, Cox B, Zhang H, Schoenfeld D; Fatty Acid Antiarrhythmia Trial Investigators. Prevention of fatal arrhythmias in high-risk subjects by fish oil n-3 fatty acid intake. Circulation 2005 Nov;112(18):2762-8.
60. O’Keefe JH Jr, Abuissa H, Sastre A, Steinhaus DM, Harris WS. Effects of omega-3 fatty acids on resting heart rate, heart rate recovery after exercise, and heart rate variability in men with healed myocardial infarctions and depressed ejection fractions. The American Journal of Cardiology 2006 Apr;97(8):1127-30.
61. Geleijnse JM , Giltay EJ, Grobbee DE, Donders ART, Kok FJ. Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. Journal of Hypertension 2002 Aug;20(8):1493-9.
62. Harris WS, Ginsberg H, Arunakul N, Shachter NS, Windsor SL, Adams M, Berglund L, Osmundsen K. Safety and efficacy of omacor in sever hypertriglyceridemia. Journal of Cardiovascular Risk 1997 Oct-Dec;4(5-6):385-91.
63. Brinton E, Mason RP. Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids in Health and Disease 2017 Jan;16(1):23.
64. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). The American Journal of Cardiology 2011 Sep;108(5):682-90.
65. Epadel [package insert, 2015 and pharmaceutical interview form, 2013]. Tokyo, Japan: Mochida Pharmaceutical Co. Ltd; 2015.
66. Vascepa [package insert, 2015]. Bedminster, NJ: Amarin Pharma Inc; 2020.
67. Maki KC, Orloff DG, Nicholls SJ, Dunbar RL, Roth EM, Curcio D, Johnson J, Kling D, Davidson MH. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial). Clinical Therapeutics 2013 Sep;35(9):1400-11.e1-3.
68. Russian National Atherosclerosis Society (RNAS); Russian Society of Cardiology (RSC); Russian Diabetes Association (RDA). Diagnostics and correction of lipid metabolism disorders in order to prevent and treat atherosclerosis. Russian recommendations, 7th revision. The Russian Journal of Atherosclerosis and Dyslipidemia 2020;1(38):47:7-40 (In Russian).
69. Russian Heart Failure Society; Russian Society of Cardiology; Russian Scientific Medical Society of Internal Medicine. Guidelines for heart failure: chronic (CHF) and acute decompensated (ADHF) diagnosis, prevention and treatment. Kardiologiia 2018;58(Supp 6):10-144 (In Russian).
70. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocrine Practice 2017 Apr;23(Suppl 2):1-87.
71. Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller M, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FK; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation 2019 Sep;140(12):e673-91.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]